Charles River Laboratories International, Inc. · CRL · Next earnings

Charles River Laboratories International, Inc. reports Wednesday, Nov 4, 2026

CRL reports before market open with consensus EPS at $2.96 and revenue at $958.5M. Last quarter: Charles River Beats Q1 Estimates as Cost Savings and NHP Internalization Drive Margin Story

Reports Before market open45 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $2.96 Calendar consensus
Consensus revenue $958.5M Calendar consensus
Report date Nov 4, 2026 Wednesday, date estimated
Session Before market open 45 days away

Where CRL left off: FY2026 Q1

Full report

Charles River Beats Q1 Estimates as Cost Savings and NHP Internalization Drive Margin Story

EPS surprise +5.1% Reported $2.06 vs $1.96
Revenue surprise +1.9% Reported $995.8M vs $977.5M
Stock move -0.0% Event window
Subsequent drift -0.2% Up to 20 sessions

Management reaffirmed full-year 2026 guidance: organic revenue flat to slightly negative, EPS $10.70-$11.20 (4-9% growth), operating margin up 20-50 bps. Guidance sentiment shifted from raised to maintained. The Q1 call provided additional margin-bridge detail, citing $100M of incremental cost savings and 120-150 bps of operating margin expansion from the $300M cumulative efficiency program.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Higher NHP sourcing costs and shipment timing affecting DSA margins
  • Stock-based compensation expense linked to CEO transition
  • Government funding uncertainty, particularly NIH budget pressures
  • Geopolitical and regulatory risk in China and broader Asia
  • Seasonality in DSA, biologics testing, and microbial solutions

Questions analysts left open

  • Seasonality and its impact on early-year demand
  • Proposal volume growth year-over-year and sequentially
  • Timeline for AI-driven drug discovery to materialize into revenue
  • Margin improvement bridge for H2: acquisitions vs cost cuts
  • Biotech early-stage revenue pacing and funding outlook

Ask FN2 about CRL next report

Transcript, numbers and history already loaded
What should I watch for in CRL's next earnings report?How did CRL guide last quarter, and is consensus above or below that?Give me the bull and bear case going into CRL earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the CRL recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent CRL quarters

All CRL earnings
-0.0%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.